Background To investigate the nationwide trend of ambulatory prescriptions of short-acting nifedipine on a PRN (pro re nata) order over a fifteen-year period in Taiwan. Methods The systematic sampling claims datasets (0.2% sampling ratio) of ambulatory care visits within Taiwan's National Health Insurance from 1997 to 2011 were analyzed. The prescriptions of short-acting capsule-form nifedipine on a PRN order were stratified by the patient's age, the prescribing physician's specialty, and the setting of healthcare facility for each year. Results During the study period, 8,189,681 visits were analyzed. While the utilization rate of calcium channel blockers changed with time from 2.8% (13,767/489,636) in 1997 to 5.1% (31,349/614,719) in 2011, that of short-acting nifedipine were from 1.0% (n = 5,070) to 0.2% (n = 1,246). However, short-acting capsule-form nifedipine on a PRN order still existed (from 447 prescriptions in 1997 to 784 in 2011). More than one half of these PRN nifedipines were prescribed by the internists and to the elderly patients; almost four-fifths of PRN nifedipines were prescribed during non-emergent consultations. Conclusion The physicians in Taiwan still had the habit of prescribing short-acting nifedipines for PRN use. The reason for such practices and the impact on patients' health deserve attention.
References
[1]
Stafford RS, Monti V, Furberg CD, Ma J (2006) Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension 48: 213–218. doi: 10.1161/01.hyp.0000229653.73128.b6
[2]
Fretheim A, Oxman AD (2005) International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res 5: 21.
Gifford RW Jr (1991) Management of hypertensive crises. JAMA 266: 829–835. doi: 10.1001/jama.266.6.829
[5]
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274: 620–625. doi: 10.1001/jama.274.8.620
[6]
Furberg CD, Psaty BM, Meyer JV (1995) Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92: 1326–1331. doi: 10.1161/01.cir.92.5.1326
[7]
Marwick C (1996) FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 275: 423–424. doi: 10.1001/jama.275.6.423
[8]
Jung SY, Choi NK, Kim JY, Chang Y, Song HJ, et al. (2011) Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology 77: 1229–1234. doi: 10.1212/wnl.0b013e318230201a
[9]
Furmaga EM, Glassman PA, Cunningham FE, Good CB (2005) Reducing the Use of Short-acting Nifedipine by Hypertensives Using a Pharmaceutical Database. In: Henriksen K, Battles JB, Marks ES, Lewin DI, Advances in Patient Safety: From Research to Implementation (Volume 3: Implementation Issues). Rockville (MD).
[10]
Bureau of National Health Insurance, Department of Health, Executive Yuan: The National Health Insurance Statistics, 2011. Available: http://www.nhi.gov.tw/English/webdata/we？bdata.aspx?menu=11&menu_id=296&WE_ID=296？&webdata_id=4229. Accessed 2013 June 26.
[11]
Su TP, Chen TJ, Hwang SJ, Chou LF, Fan AP, et al. (2002) Utilization of psychotropic drugs in Taiwan: an overview of outpatient sector in 2000. Zhonghua Yi Xue Za Zhi (Taipei) 65: 378–391.
[12]
Liu JY, Chen TJ, Hwang SJ (2001) Concomitant prescription of non-steroidal anti-inflammatory drugs and antacids in the outpatient setting of a medical center in taiwan: a prescription database study. Eur J Clin Pharmacol 57: 505–508. doi: 10.1007/s002280100349
[13]
Chen FP, Chen TJ, Kung YY, Chen YC, Chou LF, et al. (2007) Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res 7: 26. doi: 10.1186/1472-6963-7-26
[14]
Kizer JR, Kimmel SE (2000) The calcium-channel blocker controversy: historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology ‘hot topic’. Pharmacoepidemiol Drug Saf 9: 25–35. doi: 10.1002/(sici)1099-1557(200001/02)9:1<25::aid-pds469>3.0.co;2-e
[15]
Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, et al. (2008) Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol 24: 507–512. doi: 10.1016/s0828-282x(08)70627-5
[16]
Gu Q, Paulose-Ram R, Dillon C, Burt V (2006) Antihypertensive medication use among US adults with hypertension. Circulation 113: 213–221. doi: 10.1161/circulationaha.105.542290
[17]
Messerli FH, Grossman E (1999) The use of sublingual nifedipine: a continuing concern. Arch Intern Med 159: 2259–2260. doi: 10.1001/archinte.159.19.2259
[18]
Ishibashi Y, Shimada T, Yoshitomi H, Sano K, Oyake N, et al. (1999) Sublingual nifedipine in elderly patients: even a low dose induces myocardial ischaemia. Clin Exp Pharmacol Physiol 26: 404–410. doi: 10.1046/j.1440-1681.1999.03046.x
[19]
Yiu V, Orrbine E, Rosychuk RJ, MacLaine P, Goodyer P, et al. (2004) The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 19: 644–650. doi: 10.1007/s00467-004-1444-x
[20]
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114: 555–576. doi: 10.1542/peds.114.2.s2.555
[21]
Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S (2002) Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 17: 35–40. doi: 10.1007/s004670200006
[22]
Blaszak RT, Savage JA, Ellis EN (2001) The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 139: 34–37. doi: 10.1067/mpd.2001.114699
[23]
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31: 1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc
[24]
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252. doi: 10.1161/01.hyp.0000107251.49515.c2
[25]
American Geriatrics Society Beers Criteria Update Expert Panel (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60: 616–631. doi: 10.1111/j.1532-5415.2012.03923.x
[26]
Grise EM, Adeoye O, Lindsell C, Alwell K, Moomaw C, et al. (2012) Emergency department adherence to American Heart Association guidelines for blood pressure management in acute ischemic stroke. Stroke 43: 557–559. doi: 10.1161/strokeaha.111.637983
[27]
McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, et al. (2003) The quality of health care delivered to adults in the United States. N Engl J Med 348: 2635–2645. doi: 10.1056/nejmsa022615
[28]
Maxwell CJ, Hogan DB, Campbell NR, Ebly EM (2000) Nifedipine and mortality risk in the elderly: relevance of drug formulation, dose and duration. Pharmacoepidemiol Drug Saf 9: 11–23. doi: 10.1002/(sici)1099-1557(200001/02)9:1<11::aid-pds468>3.3.co;2-l
[29]
Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005) Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol 61: 531–536. doi: 10.1007/s00228-005-0974-x
[30]
Rehman F, Mansoor GA, White WB (1996) “Inappropriate” physician habits in prescribing oral nifedipine capsules in hospitalized patients. Am J Hypertens 9: 1035–1039.
